共同药业
(300966)
| 流通市值：20.95亿 | | | 总市值：31.51亿 |
| 流通股本：7666.67万 | | | 总股本：1.15亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 161,937,521.77 | 606,178,267.31 | 455,071,340.26 | 302,399,640.34 |
| 营业收入 | 161,937,521.77 | 606,178,267.31 | 455,071,340.26 | 302,399,640.34 |
| 利息收入 | - | - | - | 0 |
| 已赚保费 | - | - | - | 0 |
| 手续费及佣金收入 | - | - | - | 0 |
| 二、营业总成本 | 163,784,967.65 | 708,683,380.01 | 505,144,105.05 | 327,673,538.83 |
| 营业成本 | 124,944,641.07 | 522,680,830.27 | 370,921,722.09 | 236,564,288.07 |
| 利息支出 | - | - | - | 0 |
| 手续费及佣金支出 | - | - | - | 0 |
| 退保金 | - | - | - | 0 |
| 赔付支出净额 | - | - | - | 0 |
| 提取保险合同准备金净额 | - | - | - | 0 |
| 保单红利支出 | - | - | - | 0 |
| 分保费用 | - | - | - | 0 |
| 税金及附加 | 497,462.51 | 1,292,575.31 | 924,931.31 | 684,045.96 |
| 销售费用 | 800,352.02 | 8,755,403.03 | 5,235,386.81 | 2,656,679.29 |
| 管理费用 | 11,177,992.54 | 56,887,189.8 | 42,527,647.44 | 28,291,985.63 |
| 研发费用 | 12,314,023.44 | 69,851,019.91 | 51,357,520.12 | 35,926,201.11 |
| 财务费用 | 14,050,496.07 | 49,216,361.69 | 34,176,897.28 | 23,550,338.77 |
| 其中:利息费用 | 12,816,328.63 | 47,732,650.03 | 34,126,146.82 | 23,450,979.93 |
| 其中:利息收入 | 67,987.63 | 796,397.47 | 771,705.18 | 401,062.26 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 0.04 | 0.13 | 0.1 | 0.07 |
| 加:投资收益 | -1,363,026.18 | -265,405.91 | -358,813.61 | -219,416.42 |
| 净敞口套期收益 | 0 | - | - | 0 |
| 汇兑收益 | - | - | - | 0 |
| 资产处置收益 | -72,106.31 | -1,437,181.19 | -1,561,982.76 | -1,568,177.45 |
| 资产减值损失(新) | 0 | -10,563,099.54 | -8,604,317.73 | -3,041,689.64 |
| 信用减值损失(新) | -1,647,904.03 | -5,924,881.33 | -6,414,313.63 | -2,131,296.97 |
| 其他收益 | 3,642,556.33 | 19,710,674.87 | 14,571,130.94 | 10,414,789.05 |
| 四、营业利润 | -1,287,926.03 | -100,985,005.67 | -52,441,061.48 | -21,819,689.85 |
| 加:营业外收入 | 215,349.25 | 542,209.87 | 433,534.88 | 311,781.55 |
| 减:营业外支出 | 205,141.04 | 4,772,008.17 | 1,650,507.31 | 1,649,784.87 |
| 五、利润总额 | -1,277,717.82 | -105,214,803.97 | -53,658,033.91 | -23,157,693.17 |
| 减:所得税费用 | -2,400,300.88 | -23,488,521.63 | -16,227,711.55 | -8,503,247.47 |
| 六、净利润 | 1,122,583.06 | -81,726,282.34 | -37,430,322.36 | -14,654,445.7 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,122,583.06 | -81,726,282.34 | -37,430,322.36 | -14,654,445.7 |
| 终止经营净利润 | 0 | - | - | 0 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 3,198,531.68 | -73,359,121.23 | -32,434,878.31 | -11,152,527.25 |
| 少数股东损益 | -2,075,948.62 | -8,367,161.11 | -4,995,444.05 | -3,501,918.45 |
| 扣除非经常损益后的净利润 | 3,291,141.26 | -71,498,578.05 | -32,214,830.18 | -10,219,109.21 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | -0.64 | -0.28 | -0.1 |
| (二)稀释每股收益 | 0.03 | -0.64 | -0.28 | -0.1 |
| 八、其他综合收益 | 0 | - | - | - |
| 归属于母公司股东的其他综合收益 | 0 | - | - | - |
| 九、综合收益总额 | 1,122,583.06 | -81,726,282.34 | -37,430,322.36 | -14,654,445.7 |
| 归属于母公司股东的综合收益总额 | 3,198,531.68 | -73,359,121.23 | -32,434,878.31 | -11,152,527.25 |
| 归属于少数股东的综合收益总额 | -2,075,948.62 | -8,367,161.11 | -4,995,444.05 | -3,501,918.45 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-28 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |